esRAGE-Expressing oHSV Enhances Anti-Tumor Efficacy by Inhibition of Endothelial Cell Activation

Authors

Jessica Swanner
Ji Seon Shim
Kimberly A Rivera-Caraballo
Karina Vázquez-Arreguín
Bangxing Hong
Alberto J Bueso-Perez
Tae Jin Lee
Yeshavanth Kumar Banasavadi-Siddegowda
Balveen Kaur
Ji Young Yoo

Publication Date

3-16-2023

Journal

Molecular Therapy - Oncolytics

Abstract

High-mobility group box 1 (HMGB1) is a damage-associated molecular pattern (DAMP) molecule that plays an important role in inflammation and tumorigenesis. Receptor for advanced glycation end products (RAGE) is one of the major receptors to which extracellular HMGB1 binds to mediate its activity. RAGE is highly expressed on the endothelial cells (ECs) and regulates endothelial permeability during inflammation. Here, we introduced the endogenous secretory form of RAGE (esRAGE) as a decoy receptor for RAGE ligands into an oncolytic herpes simplex virus 1 (oHSV) (OVesRAGE), which, upon release, can function to block RAGE signaling. OVesRAGE significantly decreased phosphorylation of MEK1/2 and Erk and increased cleaved PARP in glioblastoma (GBM) cells in vitro and in vivo. oHSV-infected GBM cells co-cultured with ECs were used to test OVesRAGE effect on EC activation, vessel leakiness, virus replication, and tumor cell killing. OVesRAGE could effectively secrete esRAGE and rescue virus-induced EC migration and activation. Reduced EC activation facilitated virus replication in tumor cells when co-cultured with ECs. Finally, OVesRAGE significantly enhanced therapeutic efficacy in GBM-bearing mice. Collectively, our data demonstrate that HMGB1-RAGE signaling could be a promising target and that its inhibition is a feasible approach to improve the efficacy of oHSV therapy.

Keywords

high-mobility group box 1, HMGB1, receptor for advanced glycation end products, RAGE, endogenous secretory form of RAGE, esRAGE, glioblastoma, GBM, oncolytic herpes simplex virus 1, oHSV

Comments

Supplementary Materials